Expression of AMACR and p63 in prostate cancer and its diagnostic value
- VernacularTitle:AMACR和p63表达在前列腺癌临床诊断中的价值
- Author:
Jianhua MA
;
Jinliang BAI
;
Xiaochun YANG
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Carcinoma;
Methylacyl CoA racemase (AMACR);
p63;
Immunohistochemistry
- From:
Chinese Journal of Urology
2001;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of ?-methylacyl CoA racemase (AMACR,P504S) and p63 in prostate carcinoma tissues and the clinicopathologic significance in the diagnosis of the disease. Methods The expression of AMACR and p63 in 39 cases of prostate carcinoma and 24 cases of benign prostate lesions were examined using immunohistochemical method. The association of the AMACR and p63 expression in prostate carcinoma tissues with the differentiation and clinical staging was evaluated. Results The positive rates of AMACR and p63 were 85%(33/39) and 10%(4/39),respectively,in prostate carcinoma tissues; and those were 21%(5/24) and 88%(21/24),respectively,in benign prostatic hyperplasia. There were significant differences of these values between prostate carcinoma and benign prostatic hyperplasia (P0.05). Conclusions Over-expression of AMACR and under-expression of p63 may be the preliminary incident of the formation of prostate carcinoma,which may induce carcinoma into occurrence and progression.Thus it may be an early diagnostic parameter and a novel target for prostate carcinoma treatment.
